These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17100315)

  • 1. [Technology of immunoglobulin production. I. Technological aspects of purification].
    Volkov GL
    Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
    Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance.
    Radosevich M; Burnouf T
    Vox Sang; 2010 Jan; 98(1):12-28. PubMed ID: 19660029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulins and their use in children.
    Łaguna P; Gołębiowska-Staroszczyk S; Trzaska M; Grabarczyk M; Matysiak M
    Adv Clin Exp Med; 2015; 24(1):153-9. PubMed ID: 25923100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins.
    Miller JL; Petteway SR; Lee DC
    J Allergy Clin Immunol; 2001 Oct; 108(4 Suppl):S91-4. PubMed ID: 11586272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulins.
    Thyer J; Unal A; Thomas P; Eaton B; Bhashyam R; Ortenburg J; Uren E; Middleton D; Selleck P; Maher D
    Vox Sang; 2006 Nov; 91(4):292-300. PubMed ID: 17105604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM
    Wasserman RL; Garcia D; Greener BN; Kestenberg K; Pinkert A; Mond J; Grossman A
    Immunotherapy; 2019 Nov; 11(16):1423-1433. PubMed ID: 31596642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases.
    Blank M; Bashi T; Shoenfeld Y
    Methods Mol Biol; 2014; 1060():353-61. PubMed ID: 24037850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPLC fingerprinting approach for raw material assessment and unit operation tracking for IVIG production from Cohn I+II+III fraction.
    Peljhan S; Jakop T; Šček D; Skvarča V; Goričar B; Žabar R; Mencin N
    Electrophoresis; 2017 Nov; 38(22-23):2880-2885. PubMed ID: 28727158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
    Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
    Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities.
    José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI
    Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.
    Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP
    Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigations of prion and virus safety of a new liquid IVIG product.
    Stucki M; Boschetti N; Schäfer W; Hostettler T; Käsermann F; Nowak T; Gröner A; Kempf C
    Biologicals; 2008 Jul; 36(4):239-47. PubMed ID: 18337119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin.
    Salvatore A; Esin S; Batoni G; Ascione E; Farina C; Nardini C
    Transfusion; 2015 Jul; 55 Suppl 2():S110-6. PubMed ID: 26174888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a Premium Quality Plasma-derived IVIg (IQYMUNE
    Paolantonacci P; Appourchaux P; Claudel B; Ollivier M; Dennett R; Siret L
    PDA J Pharm Sci Technol; 2018; 72(2):176-187. PubMed ID: 29158287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
    Emmi L; Chiarini F
    Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the viral safety of immunoglobulins.
    Hellstern P
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S31-4; discussion S35. PubMed ID: 7749046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.